龍津藥業(002750.SZ)股票異動 控股股東昆明羣星投資減持295萬股
格隆匯11月13日丨龍津藥業(002750.SZ)發佈公吿,公司股票連續兩個交易日內(2022年11月10日、11月11日)收盤價格漲幅偏離值累計達到20%,根據《深圳證券交易所交易規則》的規定,屬於股票交易異常波動的情況。公司控股股東昆明羣星投資有限公司在股票交易異常波動期間通過集中競價交易方式減持公司股票295萬股,減持均價為15.20元/股,其一致行動人、公司實際控制人樊獻俄先生期間不存在買賣公司股票的情形。公司控股股東的減持行為符合公司此前披露的減持計劃,符合中國證監會和深交所的相關減持規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.